Nasus Pharma Ltd. Ordinary Shares Overview
Industry: Pharmaceutical Preparations
Sector: Healthcare
Nasus Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products addressing acute medical conditions in the community. NS002, Nasus Pharma's intranasal powder Epinephrine product candidate is being developed as a needle-free alternative to Epinephrine autoinjectors for patients with anaphylaxis. Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers needle-free, easy-to-use alternatives. Nasus Pharma's proprietary powder-based intranasal ('PBI') technology is designed for rapid and reliable drug delivery, leveraging the nasal cavity's rich vascular network for quick absorption. The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially faster, higher absorption compared to liquid-based nasal products. Nasus Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products addressing acute medical conditions in the community. NS002, Nasus Pharma's intranasal powder Epinephrine product candidate is being developed as a needle-free alternative to Epinephrine autoinj Read More
Newly listed company coverage
Verified company profile, price history, and SEC registration source are available.
10-Q/10-K financial data, or the foreign-issuer equivalent, is not available yet.
Review the SEC registration filingReported Results
No latest earnings report cached yet
Run the EDGAR earnings refresh to load the latest company-filed earnings release, 10-Q, 10-K, or transcript exhibit for this ticker.
Recent News
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Annual 10-K/20-F financial statement data is not available yet.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.